Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
1.390
-0.010 (-0.71%)
At close: Dec 5, 2025, 4:00 PM EST
1.410
+0.020 (1.44%)
After-hours: Dec 5, 2025, 7:05 PM EST
Zentalis Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Revenue | 26.87 | 67.43 | - | - | - | - | Upgrade
|
| Gross Profit | 26.87 | 67.43 | - | - | - | - | Upgrade
|
| Selling, General & Admin | 69.82 | 87.12 | 59.4 | 54.55 | 40.94 | 33.89 | Upgrade
|
| Research & Development | 109.58 | 167.77 | 189.59 | 172.73 | 166.8 | 84.9 | Upgrade
|
| Operating Expenses | 179.4 | 254.88 | 248.99 | 227.29 | 207.74 | 118.79 | Upgrade
|
| Operating Income | -152.53 | -187.46 | -248.99 | -227.29 | -207.74 | -118.79 | Upgrade
|
| Interest & Investment Income | 12.27 | 12.27 | 9.46 | 2.26 | 1.31 | 1.24 | Upgrade
|
| Earnings From Equity Investments | - | - | -16.01 | -16.28 | -1.83 | - | Upgrade
|
| EBT Excluding Unusual Items | -143.81 | -175.18 | -255.54 | -241.31 | -208.26 | -117.55 | Upgrade
|
| Impairment of Goodwill | -3.74 | -3.74 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 6.4 | 13.23 | 13.16 | 3.73 | -0.91 | -0.56 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.62 | - | - | - | 51.58 | - | Upgrade
|
| Asset Writedown | -1.2 | - | -4.95 | - | -8.8 | - | Upgrade
|
| Pretax Income | -149.52 | -165.69 | -292.91 | -237.58 | -166.39 | -118.1 | Upgrade
|
| Income Tax Expense | -0.21 | 0.18 | -0.6 | -0.47 | -0.3 | 0.44 | Upgrade
|
| Earnings From Continuing Operations | -149.32 | -165.87 | -292.31 | -237.11 | -166.09 | -118.55 | Upgrade
|
| Minority Interest in Earnings | - | 0.03 | 0.11 | 0.31 | 7.37 | 0.71 | Upgrade
|
| Net Income | -149.32 | -165.84 | -292.19 | -236.81 | -158.73 | -117.84 | Upgrade
|
| Net Income to Common | -149.32 | -165.84 | -292.19 | -236.81 | -158.73 | -117.84 | Upgrade
|
| Shares Outstanding (Basic) | 72 | 71 | 65 | 53 | 43 | 28 | Upgrade
|
| Shares Outstanding (Diluted) | 72 | 71 | 65 | 53 | 43 | 28 | Upgrade
|
| Shares Change (YoY) | 1.13% | 8.67% | 23.75% | 23.82% | 51.84% | 402.29% | Upgrade
|
| EPS (Basic) | -2.08 | -2.33 | -4.47 | -4.48 | -3.72 | -4.19 | Upgrade
|
| EPS (Diluted) | -2.08 | -2.33 | -4.47 | -4.48 | -3.72 | -4.19 | Upgrade
|
| Free Cash Flow | -134.01 | -171.08 | -208.41 | -166.3 | -160.2 | -87.58 | Upgrade
|
| Free Cash Flow Per Share | -1.87 | -2.41 | -3.19 | -3.15 | -3.75 | -3.12 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | - | - | - | - | Upgrade
|
| Operating Margin | -567.77% | -278.02% | - | - | - | - | Upgrade
|
| Profit Margin | -555.80% | -245.96% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -498.82% | -253.74% | - | - | - | - | Upgrade
|
| EBITDA | -151.63 | -186.17 | -247.6 | -225.86 | -207.2 | -118.63 | Upgrade
|
| EBITDA Margin | - | -276.11% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.9 | 1.29 | 1.39 | 1.43 | 0.54 | 0.16 | Upgrade
|
| EBIT | -152.53 | -187.46 | -248.99 | -227.29 | -207.74 | -118.79 | Upgrade
|
| EBIT Margin | - | -278.02% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.